Physician profile
Heidi Herold
NPI 1043322217
$2,157.50
in general payments reported to CMS, 2019-2025
25 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $92.79 · 2021: $16.60 · 2022: $15.40 · 2023: $368 · 2024: $773 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $560.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $328.25 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $180.20 | 2022-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $145.27 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $120.85 | 2023-2025 | Airsupra, Breztri, Tezspire |
| Exact Sciences Corporation | $99.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $98.05 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Astellas Pharma US INC | $93.48 | 2023-2024 | Veozah |
| Pfizer INC. | $80.50 | 2023-2025 | |
| Novo Nordisk INC | $74.75 | 2019-2025 | Wegovy |
| Dexcom, INC. | $62.40 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.54 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $30.64 | 2023 | |
| Boston Scientific Corporation | $28.17 | 2024 | Watchman Flx |
| Horizon Therapeutics Plc | $26.16 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $24.88 | 2025 | Thinprep 2000 Processor, Aptima |
| Edwards Lifesciences Corporation | $24.51 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Otsuka America Pharmaceutical, INC. | $22.95 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $21.74 | 2024 | Vaxelis, Gardasil, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $20.97 | 2024 | Eliquis |
| Biomerieux INC | $18.00 | 2025 | Biofire Spotfire Control Station |
| Novartis Pharmaceuticals Corporation | $16.60 | 2021 | |
| Organon LLC | $16.05 | 2025 | Nexplanon |
| Lundbeck LLC | $15.53 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.21 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Herold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.